miR-122 Represents a Novel “Host Factor” Strategy for Treatment of Hepatitis C Infection
Further Demonstration of Regulus Leadership in microRNA Science, Technology and Intellectual Property
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development CARLSBAD, Calif., Jan 11, 2010 (BUSINESS WIRE) — Regulus Therapeutics Inc., a company developing microRNA therapeutics, today announced the appointment of Zachary A.
Webinar to Discuss Recent microRNA Discoveries and Potential Applications in Medicine Scheduled for 3:00 p.m. EST on December 14, 2009
A discussion with leading microRNA scientists Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, MD, Ph.D. Professor at the Swiss Federal Institute of Technology